We present a method that permits the simultaneous analysis of carbamazepine (CBZ) and its major biotransformation products, carbamazepine-10,11-epoxide (CBZ-E) and carbamazepine-10,11-dihydroxide (CBZ-diOH), in plasma samples. The method consists of plasma extraction in alkaline medium with NaCI added using chloroform-ethyl acetate (1:1, v/v) and later purification with n-hexane. The samples were submitted to reversed-phase chromatography (RP-18) using acetonitrile-water (3:7, v/v) as the mobile phase and detection at 220 nm. Recoveries of 62.0, 99.9, and 105.4% were obtained for CBZ-diOH, CBZ-E, and CBZ, respectively, with sensitivities of 0.32 gg/mL for CBZ-E and CBZ-diOH and of 0.64 ~g/mL for CBZ. The method proved to be specific, thus permitting measurements in situations of drug combinations.
Introduction
Carbamazepine (CBZ) is a drug extensively used in the treatment of both children and adults with epilepsy. In view of the wide variation in the ability of individuals to biotransform the drug, a rational regulation of dosage requires knowledge of the relationship between dose and plasma concentration for each individual, not only for intact CBZ, but also for its biologically active biotransformation product, carbamazepine-10,11-epoxide (CBZ-E), which may represent 10-50% of the intact drug. CBZ-E is almost fully biotransformed to the biologically inactive product carbamazepine-10,11-dihydroxide (CBZ-diOH) (1) .
The biotransformation of CBZ can be induced enzymatically depending on the daily dose administered, the age of the patient, and the association with other medications, such as phenobarbital and phenytoin, which may result in a higher concentration of metabolites, CBZ-diOH in particular. Considering that the elimination of CBZ-diOH is not induced enzymatically, the CBZdiOH-CBZ ratio in plasma may be used as an indicator of the degree of induction of CBZ biotransformation (2) .
CBZ and CBZ-E levels have been measured by gas chromatography (3) (4) (5) , high-performance liquid chromatography (HPLC) (4, (6) (7) (8) (9) (10) (11) (12) (13) , or by enzyme immunoassay (4, 10, 14, 15) . The last technique only permits the quantification of CBZ, and the interference of CBZ-E leads to overestimates.. Since HPLC has been the method of choice for the analysis of CBZ and its two biotransformation products detected in plasma (16) (17) (18) (19) (20) , in the present paper we propose the use of HPLC for the simultaneous analysis of the three compounds.
Experimental
Reagents. The reagents used for drug extraction were p.a.
grade. Ethyl acetate was purified by distillation and sodium chloride was washed with ethyl acetate-chloroform (1:1, v/v) and dried in an oven at 110~ Acetonitrile, n-hexane, and methanol (Merck, Germany) were chromatography grade.
Carbamazepine, carbamazepine-10, l l-epoxide, and carbamazepine-10,11-dihydroxide (Ciba-Geigy, Switzerland) were dissolved in methanol at concentrations of 320.00, 160.00, and 160.00 lag/mL, respectively. These stock solutions were then used to prepare carbamazepine dilutions of 32.00, 8.00, 4.80, and 2.56 p.g/mL, and carbamazepine-10, 11-epoxide and carbamazepine-10, l 1-dihydroxide dilutions of 16.00, 4.00, 2.40, and 1.28 lug/mL in methanol. The internal standard, carbamazepine-10-hydroxide (CBZ-10OH, Ciba-Geigy) was prepared in methanol at a concentration of 15.00 gg/mL.
Chromatography system. The apparatus used was a Varian
Model 5000 liquid chromatography system with a Model 7125 Rheodyne injector (20-/JL loop) and a Varian Model UV-100 ultraviolet absorbance detector operating at 220 nm. Chromatograms were obtained using a Model CG-300 integrator (CG, Brazil). All analyses were performed on a 4 x 125 mm Cl8 Lichrocart | reversed-phase column (Merck) with 5-tam particles. The analytical column was protected with a 4-x 50-mm precolumn packed with Lichrospher | ODS-2 with 5-gin particles. The mobile phase was acetonitrile-water (3:7, v/v) at a flow rate of 1 mL/min.
Sample preparation, The extraction procedure consisted of the addition of 0.75 gg CBZ-10OH (internal standard), 200 ILL 1.5 M NaOH, and 50 mg NaC1 to 200 jJL plasma, extraction with 2 mL ethyl acetate--chloroform (1:1), and vortex-mixing for 1 min. After centrifugation at 1800 g for 5 rain, the organic phase was transferred to a conical tube and evaporated under an air flow at room temperature. The residue was reconstituted with 100 gL n-hexane and 100 ILL of the mobile phase, acetoni-trile-water (3:7, v/v). The material was vortex-mixed for 15 s, centrifuged at 1800 g for 10 min, and 20 taL of the lower phase was chromatographed.
The calibration curves were obtained in a similar manner after addition of 100 pL of the standard solutions of the drugs at the concentrations specified above and methanol evaporation under a constant air flow at room temperature. Calibration curves were also obtained for the drugs added to water.
Evaluation of the method. To determine absolute recovery, plasma samples containing the three drugs at the concentrations specified above were extracted in triplicate by the procedure proposed. Fifty laL of the internal standard solution (CBZ-10OH) was added to the organic phases obtained (1.5 mL) and the material was evaporated dry under an air flow at room temperature. After reconstitution with 100 IlL of the mobile phase and 100 t.tL n-hexane, the residues were chromatographed under the conditions described above.
The concentrations of these samples were calculated on the basis of the calibration curves constructed with the data for the drugs not submitted to extraction, i.e., standard solutions were dried and dissolved with the mobile phase and n-hexane and chromatographed. Relative recoveries were obtained in a similar manner, except that the internal standard was added to the plasma samples before the extraction procedure.
Blank plasma samples obtained from patients not exposed to any drugs during the last 72 hours (n = 8), with CBZ added at the concentrations of 1.60 and 12.80 lag/mL and CBZ-E and CBZdiOH added at the concentrations of 0.80 and 6.40 gg/mL were analyzed by the method proposed to determine intra-assay precision. Blank plasma with the three drugs added at identical concentrations were analyzed over five consecutive days to determine interassay precision.
Linearity was obtained by analyzing blank plasma samples in triplicate with CBZ added at the concentrations of 64.00, 32.00, 16.00, 2.40, and 1.28 lag/mL and CBZ-E and CBZ-diOH added at the concentrations of 32.00, 16.00, 8.00, 1.20, and 0.64 I.tg/mL. The concentration range was considered linear when coefficients of variation of less than 10% were obtained.
Sensitivity was determined by analyzing blank plasma samples with CBZ added at concentrations of 0.64, 0.25, and 0.13 lag/mL and with CBZ-E and CBZ-diOH added at the concentrations of 0.32, 0.13, and 0.06 gg/mL. The method was considered sensitive at the lowest concentration at which the coefficient of variation obtained in five determinations was less than I0%. Several drugs normally associated with carbamazepine were analyzed in order to determine the possible presence of interferents. The drugs with retention times close or identical to those of the drugs of interest were extracted and chromatographed.
Blood samples from patients under treatment with carbamazepine (Tegretol | tablets or syrup) were obtained in the morning with heparin (Liquemine | immediately before the administration of the drug. After centrifugation, plasma samples were stored at -20~ until the time for analysis. Figure 1 shows the chromatograms referring to (A) blank plasma, (B) plasma spiked with CBZ, CBZ-E, CBZ-diOH, and CBZ-10OH (I.S.), and (C) plasma from a patient under treatment with carbamazepine. The calibration curves obtained with water and plasma for CBZ-diOH, CBZ-E, and CBZ are presented in Figures 2 and 3 .
Results
The mean absolute recoveries determined for CBZ-diOH, CBZ-E, and CBZ were 62.4%, 103.4%, and 99.6%, respectively. Similar values (62.0%, 99.9%, and 105.4%, respectively) were obtained for the relative recoveries. Both the absolute and relative recoveries were independent of the concentrations of the three drugs. Table I shows the intra-assay and interassay coefficients of variation for the plasma concentrations of CBZ-diOH, CBZ-E, and CBZ. The method was linear at plasma concentration ranges of 0.64-32.00 lag/mL for CBZ-diOH (r= 0.976) and CBZ-E (r= 0.945), and 1.28-64.00 pg/mL for CBZ (r = 0.999). Sensitivity was 0.32 lag/mL for CBZ-diOH (CV = 5.8%) and CBZ-E (CV = 7.5%) and 0.64 pg/mL for CBZ (CV = 5.6%). Table II shows the retention times of the drugs studied as possible interferents, as well as their concentrations and the drugs detected after the extraction procedures. Table III shows the plasma CBZ-diOH, CBZ-E, and CBZ concentrations for patients under treatment with carbamazepine in combination or without other medications.
Discussion
The extraction method proposed here is simple and permits obtaining a pure extract after a single extraction step. Sodium chloride was added in order to increase the extraction yield for CBZdiOH. The yield of approximately 62.0% obtained was considered acceptable because it permitted the detection of plasma levels of the order of 0.32 t.tg/mL. The addition of sodium hydroxide was necessary to avoid interference from other antiepileptic drugs such as phenobarbital, which would also be extracted in a neutral medium.
Reconstitution of residues obtained by liquid-liquid extraction with n-hexane added to the mobile phase has been used in our laboratory to obtain greater purification of the sample injected into the chromatography apparatus. Thus, apolar impurities or impurities of low polarity extracted together with the drugs of interest are preferentially distributed in the n-hexane layer, with the consequent avoidance of indefinite retention at the top of the column. The drugs of interest, which are usually of a more polar nature, remain in the organic-aqueous (acetonitrile-water) layer, and can be injected into the chromatographic system. This procedure is of particular interest when the mobile phase contains high levels of water. In such cases, reconstitution of the residues obtained by extraction results in an extract with material in suspension which does not permit direct injection into the chromatography system. In the specific case of the present study, we noted that it was impossible to inject the sample before treatment with n-hexane. and CBZ-E at concentrations of 0.64-8.00 po/mL, and of CBZ at concentrations from 1.28-16.00 ~/mL.
As shown in Figures 2 and 3 , the linear regression equations obtained from the calibration curves in water did not differ significantly from those obtained for blank plasma. Thus, we were able to use water instead of blank plasma to obtain the calibration curves. The recovery obtained with the method was determined using two different procedures, i.e., determination of absolute and relative recoveries. Identical results, indicating 100% extraction of the intemal standard, were obtained with the two methods. CBZ, CBZ-E, and CBZ-diOH recoveries were quite satisfactory, both the absolute and relative recoveries of the three drugs being independent of the concentrations analyzed.
The linearity of the method was determined by extracting blank plasma samples with the three drugs added at concentrations of 0.64-32.00/.tg/mL for CBZ-E and CBZ-diOH, and of 1.28-64.00 lag/mL for CBZ. The method proved to be linear at these concentration ranges, which included values considered to be optimun for carbamazepine (4-12 lag/mL), as well as the values normally found in plasma for the two biotransformation products.
There are divergences in the literature about the concept of the detection limit and sensitivity. Some investigators consider the detection limit to be the smallest mass (or concentration) that produces a peak whose height is equivalent to 2-5 times the baseline noise. This concept is also sometimes considered to be sensitivity.
In the present study we considered sensitivity to be the lowest plasma concentration that could be quantified with a coefficient of variation of less than 10% (n = 5). On this basis, it was not possible to quantify plasma levels of CBZ-diOH and CBZ-E lower than 0.32 lag/mL, or plasma levels of CBZ lower than 0.64 txg/mL.
The method proved to be precise for the three drugs, both in terms of intra-assay and interassay analysis, with coefficients of variation less than 10%. The method was quite adequate in terms of specificity. None of the studied drugs interfered with the method. It should be pointed out that phenobarbital and phenytoin, normally taken in combination with carbamazepine, were not detected after the proposed extraction procedure even though their retention times are close to those of CBZ-E and CBZ, respectively. Primidone was extracted simultaneously with the three drugs studied, but its retention time was sufficiently different from the retention time of CBZ-diOH to avoid interference, except in the presence of plasma primidone concentrations close to toxic levels. However, it appears that primidone is being eliminated from current therapeutics, a fact that decreases the significance of its interference. Low CBZ-diOH levels may suffer interference from caffeine, since the retention times of the two drugs are similar.
The method has been used successfully in the analysis of carbamazepine and its biotransformation products in the plasma of carbamazepine-treated patients submitted to mono-or polytherapy (Table III) .
